Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.

Recombinant, Escherichia coli-derived outer membrane vesicles (rOMVs), which display heterologous protein subunits, have potential as a vaccine adjuvant platform. One drawback to rOMVs is their lipopolysaccharide (LPS) content, limiting their translatability to the clinic due to potential adverse effects. Here, we explore a unique rOMV construct with structurally remodeled lipids containing only the lipid IVa portion of LPS, which does not stimulate human TLR4. The rOMVs are derived from a genetically engineered B strain of E. coli, ClearColi, which produces lipid IVa, and which was further engineered in our laboratory to hypervesiculate and make rOMVs. We report that rOMVs derived from this lipid IVa strain have substantially attenuated pyrogenicity yet retain high levels of immunogenicity, promote dendritic cell maturation, and generate a balanced Th1/Th2 humoral response. Additionally, an influenza A virus matrix 2 protein-based antigen displayed on these rOMVs resulted in 100% survival against a lethal challenge with two influenza A virus strains (H1N1 and H3N2) in mice with different genetic backgrounds (BALB/c, C57BL/6, and DBA/2J). Additionally, a two-log reduction of lung viral titer was achieved in a ferret model of influenza infection with human pandemic H1N1. The rOMVs reported herein represent a potentially safe and simple subunit vaccine delivery platform.

[1]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[2]  N. Nishimura,et al.  Mechanistic Insight into the TH1-Biased Immune Response to Recombinant Subunit Vaccines Delivered by Probiotic Bacteria-Derived Outer Membrane Vesicles , 2014, PloS one.

[3]  P. Chilton,et al.  Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF , 2014, Science Signaling.

[4]  M. Kaparakis-Liaskos,et al.  Immune modulation by bacterial outer membrane vesicles , 2015, Nature Reviews Immunology.

[5]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[6]  D. Putnam,et al.  Engineered bacterial outer membrane vesicles with enhanced functionality. , 2008, Journal of molecular biology.

[7]  R. Fernandez,et al.  Recognition of lipid A variants by the TLR4-MD-2 receptor complex , 2012, Front. Cell. Inf. Microbio..

[8]  Steve E. Calvano,et al.  Acute Inflammatory Response to Endotoxin in Mice and Humans , 2005, Clinical Diagnostic Laboratory Immunology.

[9]  S. Keely,et al.  Assessment of signs of influenza illness in the ferret model. , 1989, Journal of virological methods.

[10]  M. Kuehn,et al.  Bacterial outer membrane vesicles and the host-pathogen interaction. , 2005, Genes & development.

[11]  R. Jacobi,et al.  Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets , 2015, PloS one.

[12]  N. Khardori.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011 .

[13]  W. Fiers,et al.  Natural and long-lasting cellular immune responses against influenza in the M2e-immune host , 2012, Mucosal Immunology.

[14]  G. Núñez,et al.  Nucleotide-Binding Oligomerization Domain-Like Receptors: Intracellular Pattern Recognition Molecules for Pathogen Detection and Host Defense1 , 2006, The Journal of Immunology.

[15]  U. Zaehringer,et al.  Reviewing and identifying amino acids of human, murine, canine and equine TLR4 / MD-2 receptor complexes conferring endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by Eritoran, in contrast to species-dependent modulation by lipid IVa , 2013, Computational and structural biotechnology journal.

[16]  N. Philpott,et al.  TNF-α-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Samuel I. Miller,et al.  Humanized TLR4/MD-2 Mice Reveal LPS Recognition Differentially Impacts Susceptibility to Yersinia pestis and Salmonella enterica , 2012, PLoS pathogens.

[18]  Giampiero Girolomoni,et al.  Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions1 , 2001, The Journal of Immunology.

[19]  R. Hoffmann,et al.  Vaccination with M2e-Based Multiple Antigenic Peptides: Characterization of the B Cell Response and Protection Efficacy in Inbred and Outbred Mice , 2011, PloS one.

[20]  Min-chul Kim,et al.  Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. , 2016, Vaccine.

[21]  C. Loquai,et al.  Release of IL‐12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy , 2010, Journal of leukocyte biology.

[22]  Z. Xiang,et al.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  P. Palese,et al.  Gene composition of high-yielding influenza vaccine strains obtained by recombination. , 1980, The Journal of infectious diseases.

[24]  M. Netea,et al.  From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias , 2005, Antimicrobial Agents and Chemotherapy.

[25]  Samuel I. Miller,et al.  Human Toll-like receptor 4 recognizes host-specific LPS modifications , 2002, Nature Immunology.

[26]  A. Jegerlehner,et al.  Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.

[27]  N. Costantino,et al.  E. coli genome manipulation by P1 transduction. , 2007, Current protocols in molecular biology.

[28]  T. Hartung,et al.  Assessment of pyrogenic contaminations with validated human whole-blood assay , 2009, Nature Protocols.

[29]  D. Jackson,et al.  A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. , 2015, Vaccine.

[30]  Manmohan J. Singh,et al.  Acceptable levels of endotoxin in vaccine formulations during preclinical research. , 2011, Journal of pharmaceutical sciences.

[31]  Yu-Na Lee,et al.  AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. , 2014, Vaccine.

[32]  D. Putnam,et al.  Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. , 2016, Vaccine.

[33]  M. Kuehn,et al.  NlpI-mediated modulation of outer membrane vesicle production through peptidoglycan dynamics in Escherichia coli , 2015, MicrobiologyOpen.

[34]  J. Buxbaum,et al.  A Critical Role for Human Caspase-4 in Endotoxin Sensitivity , 2014, The Journal of Immunology.

[35]  Nicole M. Bouvier,et al.  The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses , 2011, Journal of Virology.

[36]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[37]  H. Mori,et al.  Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.

[38]  D. Putnam,et al.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines , 2010, Proceedings of the National Academy of Sciences.

[39]  G. Whittaker,et al.  Variations in pH Sensitivity, Acid Stability, and Fusogenicity of Three Influenza Virus H3 Subtypes , 2014, Journal of Virology.

[40]  Y. Gho,et al.  Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. , 2009, Biochimica et biophysica acta.

[41]  Adam C. Fisher,et al.  Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies. , 2016, Cell chemical biology.

[42]  G. Schuler,et al.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. , 1999, Journal of immunological methods.

[43]  M. Koch,et al.  Structural prerequisites for endotoxic activity in the Limulus test as compared to cytokine production in mononuclear cells , 2010, Innate immunity.

[44]  J. Minei,et al.  Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care: VI. Blood glucose control in the critically ill trauma patient. , 2007, The Journal of trauma.

[45]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[46]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[47]  D. Putnam,et al.  Microbial biosynthesis of designer outer membrane vesicles. , 2014, Current opinion in biotechnology.

[48]  Tae-Young Roh,et al.  Immunization with Escherichia coli Outer Membrane Vesicles Protects Bacteria-Induced Lethality via Th1 and Th17 Cell Responses , 2013, The Journal of Immunology.

[49]  R. Compans,et al.  Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  D. Putnam,et al.  Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies , 2016, Proceedings of the National Academy of Sciences.

[51]  Roland M. Martin,et al.  The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. , 1998, Journal of immunological methods.

[52]  Sang Yup Lee,et al.  Comparative multi-omics systems analysis of Escherichia coli strains B and K-12 , 2012, Genome Biology.

[53]  J. Corchero,et al.  Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins , 2015, Microbial Cell Factories.

[54]  S. Tompkins,et al.  Genetic control of immune responses to influenza A matrix 2 protein (M2). , 2010, Vaccine.

[55]  T. Tumpey,et al.  The ferret as a model organism to study influenza A virus infection , 2011, Disease Models & Mechanisms.

[56]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[57]  C. Brayton,et al.  Immunological Variation Between Inbred Laboratory Mouse Strains , 2012, Veterinary pathology.

[58]  R. Jerala,et al.  The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex. , 2015, Molecular immunology.

[59]  A. Ensser,et al.  Autocrine TNF Is Critical for the Survival of Human Dendritic Cells by Regulating BAK, BCL-2, and FLIPL , 2012, The Journal of Immunology.

[60]  Istvan Toth,et al.  Recent progress in adjuvant discovery for peptide-based subunit vaccines , 2014, Human vaccines & immunotherapeutics.

[61]  J. Bertin,et al.  The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling. , 2014, Cell host & microbe.

[62]  M. Kuehn,et al.  Offense and defense: microbial membrane vesicles play both ways. , 2012, Research in microbiology.

[63]  M. Kuehn,et al.  Outer Membrane Vesicle Production by Escherichia coli Is Independent of Membrane Instability , 2006, Journal of bacteriology.